The investigators will evaluate the safety of a single endovenous infusion of ICOVIR5 in adults with locally advanced and metastatic melanoma. ICOVIR5 consists in a conditionally replicative or oncolytic adenovirus.

Inclusion Criteria:

• Malignant melanoma advanced or metastatic.
• Other than 18 years
• Karnofsky index > 60 %
• Life expectancy > 3 months
• ALT/AST <=2.5 times the upper normal limit
• Creatinine clearance >= 50 ml/min.
• Bilirubin <25 umol/l
• Alkaline phosphatase <= 2.5 time upper normal limit
• Normal bone marrow function: Neutrophils >=1.5 E9/L, platelets >= 1E11/L, hemoglobin >= 100 g/l, Normal prothrombin time and thromboplastin time,
• HIV negative
• Measurable disease
• Signed informed consent.

Exclusion Criteria:

• Geographical, social or psychological conditions that may impair the protocol compliance.
• Active infections or other severe medical status.
• History of liver disease.
• Other or concomitant treatments for melanoma or investigational product.
• Previous participation in studies with adenovirus.
• Virus diseases diagnosed two weeks before inclusion.
• Immunosuppressive concomitant treatments
• Concomitant malignant haematological disease.
• Patients having family members with immunodeficient status or disease
• Patients with Li Fraumeni syndrome or germinal retinoblastoma gene defects.